MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer

Table 2

Worst toxicity expressed as N (%) during CCRT (RTOG criteria).

	Grade 1	Grade 2	Grade 3	Grade 4
Anemia	12(32)	6(16)	1(3)	0(0)
Neutropenia	3(8)	13(35)	7(19)	0(0)
Leucopenia	4(11)	11(30)	11(30)	0(0)
Thrombocytopenia	4(11)	3(8)	2(5)	0(0)
Nausea/vomiting	11(30)	5(14)	1(3)	0(0)
Fatigue	5(14)	9(24)	3(8)	0(0)
Dysphagia/anorexia	2(5)	14(38)	7(19)	0(0)
Weight Loss	2(5)	2(5)	1(3)	0(0)
Dermatitis	3(8)	7(19)	2(5)	0(0)
Rash	8(22)	12(32)	3(8)	1(3)
Mucositis	9(24)	9(24)	5(14)	0(0)
Mouth dryness	6(16)	7(19)	0(0)	0(0)
Constipation	10(27)	1(3)	1(3)	0(0)
Diarrhea	0(0)	1(3)	1(3)	0(0)
Infection	2(5)	0(0)	1(3)	0(0)
HSR	4(11)	2(5)	0(0)	0(0)
Otitis	0(0)	3(8)	0(0)	0(0)
Hoarseness	3(8)	4(11)	1(3)	0(0)
Peripheral Neuropathy	0(0)	1(3)	0(0)	0(0)
Nephrotoxicity	0(0)	1(3)	0(0)	0(0)
Confusion	1(3)	0(0)	0(0)	0(0)
Dizziness	3(8)	0(0)	0(0)	0(0)
Pruritus	2(5)	0(0)	0(0)	0(0)
Bleeding	3(8)	0(0)	0(0)	0(0)
Pain	1(3)	1(3)	0(0)	0(0)
Dry skin	1(3)	0(0)	0(0)	0(0)
Memory loss	1(3)	0(0)	0(0)	0(0)
Seizure	1(3)	0(0)	0(0)	0(0)